Allergy Shot Alternative with Sublingual Treatment Plans | Wyndly logo

No U.S. tree‑pollen tablet: how to treat tree pollen (drops vs shots)

What U.S. regulators have cleared (and what they haven’t)

  • As of December 2025, the U.S. Food and Drug Administration (FDA) has approved only four sublingual immunotherapy (SLIT) tablets: grass (GRASTEK; ORALAIR), ragweed (RAGWITEK), and house‑dust‑mite (ODACTRA). There is no FDA‑approved tablet for any tree pollen (e.g., birch, oak, cedar, alder, maple). [See Footnotes 1–3.]

  • Allergy shots (subcutaneous immunotherapy, SCIT) remain FDA‑regulated and widely used for tree pollen. SLIT drops (custom liquid allergen extracts placed under the tongue) are used off‑label in the U.S. for tree pollens. [Footnotes 4–7.]

What this means for tree‑pollen allergy patients

If you’re allergic to tree pollens (birch, oak, cedar/juniper, alder, maple, etc.), your long‑term disease‑modifying options in the U.S. today are:

  • Allergy shots (SCIT) formulated for your specific tree allergens

  • Off‑label SLIT drops formulated from tree‑pollen extracts

Both approaches are forms of allergen immunotherapy that retrain the immune system rather than just masking symptoms. High‑quality evidence supports immunotherapy for allergic rhinitis and conjunctivitis; SLIT tablets are FDA‑approved for certain allergens, while SLIT drops are supported by randomized trials and meta‑analyses but are not FDA‑approved products in the U.S. [Footnotes 4–8.]

Tree‑pollen treatment options at a glance

Feature SLIT drops (off‑label) Allergy shots (SCIT)
U.S. FDA status for tree pollen Not FDA‑approved products (physician‑prescribed off‑label use of allergen extracts) FDA‑regulated allergy extracts and protocols
Evidence for efficacy in allergic rhinitis/conjunctivitis Multiple RCTs/meta‑analyses show symptom and medication score reductions for SLIT; most tablet data are for grass/ragweed/HDM; drops evidence is broader internationally Extensive RCT/meta‑analysis support across inhalant allergens, including trees
Dosing & setting Daily at home; first dose typically observed in clinic Weekly build‑up in clinic, then maintenance every 2–4 weeks (in‑office due to anaphylaxis monitoring)
Multi‑allergen treatment Can address multiple pollens (e.g., multiple trees ± other triggers) in one plan Can address multiple allergens via tailored vials
Safety profile Mostly mild local oral/throat itching; severe reactions are rare; epinephrine auto‑injector is prescribed as precaution Local arm reactions common; systemic reactions uncommon but possible; post‑injection observation required
Onset/trajectory Improvement often within 6–24 weeks; full benefit accrues over 3–5 years Improvement often within 6–12 months; full benefit accrues over 3–5 years
Insurance Typically not covered; HSA/FSA often eligible Often covered (copays/visit time apply)

[Footnotes 4–10.]

Off‑label drops, evidence, and safety (for tree pollen)

  • Evidence: Cochrane and other systematic reviews of SLIT show clinically meaningful reductions in symptoms and medication use versus placebo, with favorable safety; most FDA‑labeled tablet data are for grass/ragweed/HDM, while off‑label liquid drops are supported by international trials and practice guidelines. [4–8]

  • Safety: SLIT mainly causes transient mouth/throat itching; severe systemic reactions are rare compared with shots. First dose is generally supervised; patients are trained and prescribed epinephrine. [4–7]

  • Regulatory note: In the U.S., only the tablets listed above are FDA‑approved SLIT products. Custom multi‑allergen SLIT drops are compounded from FDA‑licensed extracts but are not themselves FDA‑approved. [1–3,7]

When shots may be preferable

  • You want in‑network coverage and are comfortable with clinic visits

  • You have complex asthma/airway disease and your specialist prefers in‑office escalation/monitoring

  • You previously responded well to SCIT and want to resume a known regimen

Clinical timelines and expectations

  • Expect noticeable improvement with SLIT drops in roughly 6–24 weeks, with durable benefit after 3–5 years of consistent therapy. Shots often take 6–12 months for comparable improvement, with durable benefit after 3–5 years. [4–6,9–10]

  • Either path should be supervised by a clinician who can match extract content and dose to your sensitization profile (ideally via specific IgE testing and clinical history).

Cost, access, and practicality

  • Shots: Usually covered but require frequent in‑office visits (travel and time costs). [10]

  • SLIT drops: Typically out‑of‑pocket in the U.S.; convenient at home; may suit patients who live far from clinics, travel often, or prefer needle‑free care. [4–7]

How Wyndly approaches tree‑pollen care

Wyndly is a physician‑led telehealth practice focused on environmental allergies. For tree‑pollen allergies we:

1) Identify your triggers with a CLIA‑certified at‑home test covering 40+ indoor/outdoor allergens (trees, grasses, weeds, dust mites, molds, pets). 2) Review results with a board‑certified physician and design a personalized plan. 3) Prescribe immunotherapy:

  • SLIT drops (off‑label) for individualized multi‑allergen care at home, or

  • SLIT tablets (when appropriate for grass/ragweed/HDM), or

  • Coordinate SCIT locally if shots are your preference. 4) Provide ongoing medical support; most patients notice improvement within 4–24 weeks, with a typical course of ~3 years for sustained relief.

Key details: $99/month for treatment (HSA/FSA eligible), 90‑day Allergy‑Free Guarantee, ages 5+, environmental allergies only (not food). Contraindications include eosinophilic esophagitis (EoE), uncontrolled asthma, pregnancy, or beta‑blocker use—your doctor will screen for safety.

Footnotes (selected sources)

1) FDA allergen SLIT tablets roster (ODACTRA, GRASTEK, ORALAIR, RAGWITEK) — fda.gov (Allergen Extract Sublingual Tablets page). 2) ODACTRA (house‑dust‑mite SLIT tablet) — FDA product page and label updates (2017–2025). 3) GRASTEK (Timothy grass), ORALAIR (five grasses), RAGWITEK (short ragweed) — FDA product pages/labels. 4) UpToDate patient review: SLIT is approved in the U.S. only as tablets for certain pollens/dust mite; liquid drops are not FDA‑approved. 5) Cochrane Review (2010 update): SLIT reduced symptoms/medication use vs placebo; no severe systemic reactions reported across pooled trials. 6) Cochrane Review (ocular symptoms in ARC/AC): SLIT improves allergic conjunctivitis symptom scores. 7) AAAAI patient guidance: SLIT tablets (brands/indications), boxed‑warning precautions, first‑dose observation, epinephrine training. 8) AAFP summary of AAO‑HNSF guideline: offer immunotherapy (SCIT or SLIT) to appropriate allergic‑rhinitis patients. 9) Typical immunotherapy timelines: relief during the first treatment year; durable benefit after ~3–5 years of therapy — summarized across Cochrane/clinical guidance. 10) Practical access/coverage: in‑office monitoring for shots; SLIT’s at‑home convenience with safety precautions — summarized across AAAAI/AAFP/clinical sources.